Gist: A Review
DOI:
https://doi.org/10.3329/jss.v16i2.43608Keywords:
GIST, Rhabdomyoma, lmatinibAbstract
Non-epithelial tumours of stomach and intestine were described and termed as leomyomas because they possessed smooth muscle features when examined under light microscopy.Recently cell of origin of these tumourshave been identified as a pluripotential mesenchymal stem cell programmed to differentiate into the interstitial cells of Cajal. Gastrointestinal stromal tumours (GIST) is widely accepted term used for these tumours.GISTs are not infrequent and can occur in any part of GI Tract and also may be extraintestinal in origin. Introduction of lmatinib, a Tyrosine Kinase Inhibitor [TKI] for treatment of GIST has made a great impact in the management options of these tumours which were refractory to majority of available cytotoxic drugs. High response rate to imatinib generated new research for newer drugs on one hand and defining genetic structure and changes in other tumours to develop more pecific and successful therapy.This review is an effort to consolidate present understanding and information about pathology diagnosis and management of GIST.
Journal of Surgical Sciences (2012) Vol. 16 (2) : 86-97
Downloads
21
48
Downloads
Published
How to Cite
Issue
Section
License
No part of the materials published in this Journal may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher. Reprints of any article in file Journal will be available from the publisher.